Breast Cancer

Karen Durham never expected to be speaking on behalf of the Metastatic Breast Cancer Alliance

The PD-1 inhibitor Keytruda (pembrolizumab) has demonstrated promising clinical activity with an acceptable safety profile in heavily pretreated patients with recurrent metastatic triple-negative breast cancer (TNBC).

When 34-year-old Jen Levinson was diagnosed with stage 2 breast cancer in 2000, the breast cancer world gained a powerful advocate -- but it wasn't Jen, it was her mother.

Debu Tripathy, editor-in-chief of CURE magazine, recaps the first day of the San Antonio Breast Cancer Symposium - namely the advances in treating breast cancer with immunotherapy.

Abraxane (nab-paclitaxel) proved markedly more effective than conventional paclitaxel as part of a neoadjuvant regimen for patients with high-risk, early breast cancer, according to results presented at the 2014 San Antonio Breast Cancer Symposium.

Andrea Ivory had an epiphany shortly after being diagnosed with breast cancer in 2004 at age 45.

The annual meeting of the European Society for Medical Oncology (ESMO) was held in September to discuss the latest data on critical issues in cancer treatment, diagnostics, prevention, supportive care and more.

Women with breast cancer who practice yoga during radiation treatment receive a number of benefits that appear to have long-term durability.

A recent survey reveals that most women aren't aware of the association between dense breast tissue and breast cancer risk.

Given the mixed messages involved, it's not surprising that women with ductal carcinoma in situ can become anxious and sometimes unduly alarmed by the diagnosis.

Susan Hope Schaffer, the 2014 Oncology on Canvas overall winner, shares how her experience with breast cancer helped her evolve as an artist.

Being a parent affects EVERY decision in my life, even the ones regarding my cancer care.

Breast cancer is a complicated family of diseases – the goal is personalized medicine, and a team-based approach should be the standard of care.

Lobular carcinoma in situ, or LCIS, is considered a risk factor for invasive cancer. 

The condition can be managed, and new treatments are being investigated.

Will suspicious cells remain idle or become aggressive breast cancers?

The NCNN recommends testing for Lynch syndrome for at-risk individuals, regardless of whether they have colorectal cancer.

Written by a husband who supported his wife through her illness, Husband’s Guide to Breast Cancer offers a straightforward game plan to guide men in their role as caregiver.

Maintaining bone health is essential throughout cancer treatment.

The latest in cancer prevention, diagnosis and treatment.

When deciding on a cancer treatment—and determining its effectiveness—look for a biomarker.

Biomarkers can estimate cancer risk, screen for the disease and confirm a diagnosis.

One alternative to targeting specific tumor-associated proteins is to entice the patient’s immune system to attack the tumor directly.

Focusing on screening and genetic clues, progress in lung cancer shifts forward.

People with cancer should ask questions about what biomarker tests are offered for their cancer type, what those tests offer and what they don't.

David Spigel, a lung cancer specialist, explains the potential of biomarkers in the search for new treatments.

Clinical trial results suggests that pathologic complete response after HER2-positive therapy equates to great survival.

Small Yet Significant Steps in Treating Triple-Negative Breast Cancer

Aromatase inhibitors may help prevent breast cancer.

When it comes to relieving joint pain from aromatase inhibitors, motion is lotion.